Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

The National Institutes of Health (NIH) is planning to freeze the flow of funds to institutions outside of the U.S., ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

The National Institutes of Health (NIH) is following in the FDA’s footsteps—away from animal testing.  | The National ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

Chris Smyth, Ph.D., is leaving his post as president of Icon Biotech to take the helm at Comac Sept. 1, the company said in ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

Biopharma venture funding dropped 20% in the first quarter of 2025 compared to the same period the year before, according to ...

An investor is ratcheting up the pressure on Acelyrin to pull out of a planned merger with Alumis, setting out its case for ...